Hypertension is a significant health condition that increases the risk of several other diseases, including renal failure, myocardial infarction, stroke, and death. Angiotensin-converting enzyme inhibitors (ACE-Is) are part of most protocols used to manage hypertension and various other conditions, including congestive heart failure and myocardial infarction. Even though these therapies are well tolerated, one in every five individuals discontinues them due to adverse medication reactions, the most prevalent of which is a persistent dry cough. Heritability accounts for 30% to 50% of inter-individual variation in blood pressure. However, the genetic variation connected to ACE-I-induced cough remains contentious and requires additional investigation. In addition, genetic variation may affect the incidence of ACE-I-related cough. This article examines ACE-Is' efficacy, their adverse effects, and pharmacogenetic studies on ACE-I-induced cough.